Related Experiment Video

Updated: Jun 9, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and

Olga Zolochevska1, Marxa L Figueiredo

  • 1Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana 70803, USA.

The Prostate
|September 3, 2010
PubMed
Abstract

Insights

The novel protein cdk2-associated protein 1 (cdk2ap1) and bicalutamide (CDX) combination show promise in inhibiting prostate cancer progression. This combination reduces cancer cell invasiveness and harmful interactions with bone cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Prostate cancer cell cycle and apoptosis are regulated by cdk2-associated protein 1 (cdk2ap1).
  • cdk2ap1's potential to reduce prostate cancer invasiveness and interactions with bone cells was unexplored.
  • The combination of cdk2ap1 and bicalutamide (CDX) was investigated for enhanced inhibition of cancer cell phenotypes.

Purpose of the Study:

  • To determine if cdk2ap1 can reduce prostate cancer invasiveness and malignant interactions with bone cells.
  • To evaluate if combining cdk2ap1 with bicalutamide (CDX) enhances the inhibition of prostate cancer cell phenotypes.

Main Methods:

  • Stable expression of cdk2ap1 in prostate cancer cell lines using lentiviral vectors.
  • Co-culture assays were employed to quantify cellular invasion, migration, and interactions with the bone microenvironment.
  • Analysis of signaling pathways involved in prostate cancer and bone cell crosstalk.

Main Results:

  • cdk2ap1 augmented the effects of CDX on cell-cycle arrest, growth inhibition, and invasion.
  • Both cdk2ap1 and the cdk2ap1/CDX combination reduced cancer cell chemotaxis towards osteoblasts.
  • Prostate cancer/bone crosstalk signaling pathways were modulated by cdk2ap1 and CDX.

Conclusions:

  • cdk2ap1 and the cdk2ap1/CDX combination show potential in regulating prostate cancer growth and malignant phenotypes.
  • These agents may reduce procarcinogenic interactions between prostate cancer and the bone microenvironment.
  • The combination therapy holds promise for restoring malignant phenotypes and signaling to a more benign state.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.